Avifavir® is effective against various variants of coronavirus, including Delta and Omicron, as it affects the highly ...

Avifavir® is the first product approved in Russia for treatment of coronavirus and the world-first registered product ...

Chromis, a joint venture of the Russian Direct Investment Fund (RDIF) and ChemRar Group, was rated by Rospatent among ...

The high efficacy of Avifavir®, the first registered drug for the treatment of COVID-19, in clinical practice was ...

Indonesia registers Russian drug with proven clinical efficacy against coronavirus Avifavir was the first ...

Chromis (Russia), a joint venture of the ChemRar Group and the Russian Direct Investment Fund (RDIF), and its partner ...

The results of the two phases of the clinical trial of Avifavir for coronavirus treatment were presented at the ...

Under the Government order on financing the purchase of drugs for the treatment of outpatients with the COVID-19 ...

 Efficacy of favipiravir-based drugs against COVID-19 has been confirmed by clinical trials in Russia and Japan ...

Moscow, September 23, 2020 – The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar ...

Moscow, September 21, 2020 – The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar ...

Moscow, August 3, 2020 – Chromis, a joint venture established by the Russian Direct Investment Fund (RDIF), Russia’s ...